<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01546532</url>
  </required_header>
  <id_info>
    <org_study_id>CRLX030A2202</org_study_id>
    <secondary_id>2011-001588-37</secondary_id>
    <nct_id>NCT01546532</nct_id>
  </id_info>
  <brief_title>Renal Hemodynamic Effects of RLX030A in Subjects With Chronic Heart Failure (CHF)</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the Renal Hemodynamic Effects of RLX030 and Placebo Infused for 24 Hours in Subjects With Chronic Heart Failure (CHF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will assess the renal hemodynamic effect of RLX030 infusion in subjects with
      chronic heart failure. In addition safety and effects on renal function and biomarkers will
      be assessed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in renal plasma flow (RPF) measured by Para-aminohippuric acid (PAH) clearance in subjects with CHF after 24 hours intravenous (i.v) infusion of RLX030</measure>
    <time_frame>Baseline, during and after the end of 24 hours infusion</time_frame>
    <description>Serial blood and urine collections over time for determination of PAH and its clearance respectively</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in glomerular filtration rate (GFR) as measured by Iothalamate (IOTH) clearance in subjects with CHF after 24 hours i.v. infusion of RLX030</measure>
    <time_frame>Baseline, during and after the end of 24 hours infusion</time_frame>
    <description>Serial blood and urine collections over time for determination of IOTH and its clearance respectively</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in filtration fraction (FF) in subjects with CHF after 24 hours infusion of RLX030</measure>
    <time_frame>Baseline, during and after the end of 24 hours of infusion</time_frame>
    <description>The filtration fraction (FF) is derived as the ratio of GFR divided by RBF in percent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change over time in Diuresis</measure>
    <time_frame>During 24 hours of infusion and after the end of the infusion</time_frame>
    <description>Urine samples will be collected for analyses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change over time in calculated creatinine clearance</measure>
    <time_frame>During 24 hours of infusion and after the end of the infusion</time_frame>
    <description>Urine samples will be collected for analyses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change over time on fractional sodium excretion(natriuresis)</measure>
    <time_frame>During 24 hours of infusion and after the end of the infusion</time_frame>
    <description>Urine samples will be collected for analyses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central aortic systolic pressure-time curve</measure>
    <time_frame>During 24 hours of infusion and after the end of the infusion</time_frame>
    <description>A cuff will be used for a brachial blood pressure measurement and a wrist sensor for arterial pulse waveforms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radial augmentation index-time curve</measure>
    <time_frame>During 24 hours of infusion and after the end of the infusion</time_frame>
    <description>A cuff will be used for a brachial blood pressure measurement and a wrist sensor for arterial pulse waveforms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events, serious adverse events and death</measure>
    <time_frame>During 24 hours of infusion and after the end of the infusion</time_frame>
    <description>Monitoring of adverse events, serious adverse events and death from screening to end of study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of RLX030: area under the serum concentration-time curve from time zero to infinity (AUCinf)Time</measure>
    <time_frame>During 24 hours of infusion and for 24 hours after the end of infusion</time_frame>
    <description>Blood will be collected from an indwelling catheter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of RLX030: area under the serum concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast)</measure>
    <time_frame>During 24 hours of infusion and for 24 hours after the end of infusion</time_frame>
    <description>Blood will be collected from an indwelling catheter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of RLX030: serum concentration over 20 hours of infusion (C24h)</measure>
    <time_frame>During 24 hours of infusion and for 24 hours after the end of infusion</time_frame>
    <description>Blood will be collected from an indwelling catheter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of RLX030: terminal elimination half-life (T1/2)following intravenous administration</measure>
    <time_frame>During 24 hours of infusion and for 24 hours after the end of infusion</time_frame>
    <description>Blood will be collected from an indwelling catheter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of RLX030: mean residence time (MRT)intravenous administration</measure>
    <time_frame>During 24 hours of infusion and for 24 hours after the end of infusion</time_frame>
    <description>Blood will be collected from an indwelling catheter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of RLX030: volume of distribution at steady state (Vss) following intravenous administration</measure>
    <time_frame>During 24 hours of infusion and for 24 hours after the end of infusion</time_frame>
    <description>Blood will be collected from an indwelling catheter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of RLX030: systemic clearance from serum (CL) following intravenous administration(natriuresis)</measure>
    <time_frame>During 24 hours of infusion and for 24 hours after the end of infusion</time_frame>
    <description>Blood will be collected from an indwelling catheter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corrected QT (QTc) Interval Using Fridericia's and Bazett's Formula</measure>
    <time_frame>Baseline, during the 24 hours of infusion and after the end of the infusion</time_frame>
    <description>Continuous 12 lead Holter ECG monitoring for extraction of ECGs and analysis</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">118</enrollment>
  <condition>Chronic Heart Failure (CHF)</condition>
  <arm_group>
    <arm_group_label>RLX030</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RLX030 as intravenous infusion for 24 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo as intravenous infusion for 24 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RLX030</intervention_name>
    <description>RLX030 as intravenous infusion for 24 hours.</description>
    <arm_group_label>RLX030</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intravenous infusion of Placebo over 24 hours</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent must be obtained before any assessment is performed.

          -  Male and female heart failure patients with body weight &lt;160 kg, on standard therapy
             including a stable dose of furosemide 40-240 mg/day orally (p.o). or equivalent dose
             of loop diuretics, reduced systolic function (LVEF ≤ 45% measured within the past 6
             months), BNP ≥ 100 pg/mL or NT-pro-BNP of ≥ 400 pg/mLNYHA Class II or III, and
             worsening symptoms, e.g. fatigue, dyspnea, breathlessness within 3 months

          -  Mild to moderate renal impairment

        Exclusion criteria:

          -  Systolic blood pressure (SBP) &lt; 110 mm Hg at the time of randomization

          -  Administration of intravenous radiographic contrast agent within 72 hours prior to
             randomization or acute contrast-induced nephropathy at the time of randomization

          -  Current use of non-steroidal antiinflammatory drugs (NSAIDs)

          -  Current or planned (through the completion of study drug infusion) treatment with any
             i.v. therapies, including vasodilators (including nesiritide), positive inotropic
             agents, vasopressors, levosimendan, or mechanical support (intra-aortic balloon pump,
             endotracheal intubation, mechanical ventilation, or any ventricular assist device).

          -  Clinically significant hepatic impairment defined as hepatic encephalopathy of any
             degree or total bilirubin &gt; 50 μmol/l (3 mg/dl) or, if patient is not on warfarin
             therapy, INR &gt; 2.0 (or Prothrombin Time &gt; 2 * ULN)

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Goettingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Deventer</city>
        <zip>7416 SE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sneek</city>
        <zip>8601 ZR</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Grodzisk Mazowiecki</city>
        <zip>05-825</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Katowice</city>
        <zip>40-637</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Krakow</city>
        <zip>31-202</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kraków</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lublin</city>
        <zip>20-954</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Walbrzych</city>
        <zip>58-309</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Warszawa</city>
        <zip>04-628</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2012</study_first_submitted>
  <study_first_submitted_qc>March 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2012</study_first_posted>
  <disposition_first_submitted>May 20, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>May 20, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 15, 2015</disposition_first_posted>
  <last_update_submitted>May 20, 2015</last_update_submitted>
  <last_update_submitted_qc>May 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart failure</keyword>
  <keyword>RLX030</keyword>
  <keyword>hemodynamics</keyword>
  <keyword>cardiovascular diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

